New: NCI-funded clinical trial search
Mednet Logo

How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?

Is deferring chemotherapy based on low oncotype acceptable in setting of recurrence? Would you recommend using a different AI, Tamoxifen, or Fulvestrant as endocrine therapy if Exemestane was used for initial breast cancer 3 years ago?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Lewisburg Cancer Center | Evangelical Hospital
Answered on

The question does not provide the details of recurrence as to whether this is a locoregional breast recurrence, with or without lymph node or chest wall involvement. Ipsilateral or contralateral or second primary? Prior lumpectomy margins, prior type, and extent of radiation therapy? Time to recurrence from prior locoregional and systemic therapy, and duration of prior systemic hormonal therapy, are all important in defining the management of this case.

Over the last 3 decades, only two prospecti...

Join for free or sign in to see the full answer

Mednet Member
Medical Oncology · Banner MD Anderson Cancer Center
Answered on

In the CALOR trial that studied chemo vs. no chemo after resection of isolated locoregional recurrence, there is benefit of adjuvant chemotherapy. The 5-year HR for DFS with chemo was 0.59. The 5-year HR for OS with chemo was 0.41. The benefit was mainly seen in HR- patients. This patient has a very small node negative HR+ recurrence that was apparently resected, I would say the benefit of adjuvant chemotherapy would be very minimal and that the benefit and risk ratio would not justify chemother...

Join for free or sign in to see the full answer